• Vaccine Name: Pfs230D1-EPA/Matrix-M
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: Pfs230 domain 1 (Duffy et al. 2021)
• Pfs230 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Expressed by gametocytes in the human stage of P. falciparum. Also a surface antigen of gametes and zygotes in the mosquito stage. Mediates binding of exflagellating microgametes to red blood cells. (Coelho et al., 2021)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: Malaria transmission blocking vaccine: block parasite transmission through mosquitoes (Coelho et al., 2021)

Human Response

• Host Strain: Adults in Mali
• Host age: 18 - 50 years old
• Host gender: all
• Vaccination Protocol: Phase I, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial. Ongoing.
  Participants are randomly assigned to different groups, getting 3 doses of 1) 160 µg/mL conjugated Pfs230D1M and 124 µg/mL conjugated EPA or 2) 160 µg/mL conjugated Pfs230D1M and 143 µg/mL conjugated EPA or 3)Verorab Rabies, each dose injected at 0, 1, and 2 months.
  Outcome Measures:
  Primary: Number of local and systemic adverse events (AEs) and serious adverse events (SAEs) to assess the safety of the study drug
  Secondary: 1) Level of humoral immune response as measured by ELISA titer response to Pfs230D1M after third immunization. 2) Duration of humoral immune response as measured by ELISA titer response to Pfs230D1M after third immunization. 3) Level of functional antibody response to Pfs230D1M as measured by standard membrane feeding assay (Duffy et al. 2021)